HealthAdaptive Biotechnologies Highlights New Myeloma Cure Criteria
Adaptive Biotechnologies emphasized a new consensus definition for curing multiple myeloma. The criteria require patients to remain in complete remission for five years without treatment and maintain sustained minimal residual disease (MRD) negativity. This new standard aims to better define and measure cure in multiple myeloma patients.
Rttnews·14h ago



